Singapore markets close in 2 hours 56 minutes
  • Straits Times Index

    +16.44 (+0.52%)
  • Nikkei

    +180.71 (+0.62%)
  • Hang Seng

    +285.16 (+1.12%)
  • FTSE 100

    -30.20 (-0.42%)

    +68.18 (+0.11%)
  • CMC Crypto 200

    +7.93 (+0.55%)
  • S&P 500

    +15.09 (+0.34%)
  • Dow

    -36.15 (-0.10%)
  • Nasdaq

    +124.47 (+0.84%)
  • Gold

    +11.20 (+0.63%)
  • Crude Oil

    +0.37 (+0.45%)
  • 10-Yr Bond

    0.0000 (0.00%)
  • FTSE Bursa Malaysia

    +13.45 (+0.84%)
  • Jakarta Composite Index

    -30.09 (-0.45%)
  • PSE Index

    +46.50 (+0.64%)

3 Day Course on Pharmacovigilance Training: December 6-8, 2021 -

·4-min read

DUBLIN, September 27, 2021--(BUSINESS WIRE)--The "Pharmacovigilance Training Course" conference has been added to's offering.

This comprehensive three-day course has been designed to provide an introductory guide for all those concerned with pharmacovigilance. The interactive programme will cover topics from basic pharmacovigilance principles and terminologies through to the current regulatory framework and its global impact, including drug surveillance in the EU, US and Japan. Proactive pharmacovigilance pre- and post-marketing will be addressed as will risk management, the challenges of causality assessments, and effective signal detection.

Our panel of experts will offer practical guidance throughout the course and use real-world examples and case studies to contribute to the development of your knowledge. There will also be ample opportunity to share experiences with the speakers and fellow professionals, which will further enhance your understanding of pharmacovigilance issues.

Key topics to be addressed include:

  • Principles of pharmacovigilance and data resources

  • Risk management, causality assessment and post authorisation safety and efficacy studies (PASS/PAES)

  • Pharmacoepidemiological studies and evolution of periodic safety update reports (PSURs), periodic benefit-risk evaluation reports (PBRERs) and development safety update reports (DSURs)

  • Proactive pharmacovigilance pre- and post-marketing, risk-benefit assessment

  • Pharmacovigilance regulations, clinical trial ADR reporting requirements n Drug surveillance in countries outside Europe

  • Drug surveillance in countries outside Europe

  • Post-marketing surveillance: observational cohort studies

  • An overview of signal detection and risk management plans (RMPs)

Key Topics Covered:

Principles of pharmacovigilance and data resources

  • Basic principles of monitoring drug safety

  • An overview of the methodology

  • Data resources available for monitoring and evaluating drug safety

  • Responding to drug safety signals

Risk management and risk minimisation: basic principles

  • Basic principles

  • Proactive strategies

  • Principles of risk minimisation

  • PASS and PAES

Causality assessment: clinical diagnosis of adverse events

  • The principles of causality assessment with practical examples

  • Medical evaluation of individual reports of adverse events

  • Strategies for follow-up

The current regulatory framework and its global impact

  • Overview of European regulatory framework, including 2012 EU pharmacovigilance legislation

  • Implications for the global environment - the links to ICH and CIOMS recommendations

  • Inspections and penalties for non-compliance

  • Practical applications of definitions

European post-marketing pharmacovigilance regulations

  • The role of the Pharmacovigilance Risk Assessment Committee (PRAC) and SCOPE initiative

  • Quality management systems and the pharmacovigilance system master file (PSMF)

  • QPPV

  • Expedited reporting: solicited vs spontaneous

  • Periodic reports and signal management and use of EudraVigilance

  • RMPs and risk minimisation


  • Additional monitoring

  • Pharmacovigilance inspections/audit

  • Public hearings including first EMA hearing - September 2017

  • Stakeholder involvement initiatives such as PROTECT, WEB-RADR

  • New electronic reporting standards, E2B (R3), IDMP

Proactive pharmacovigilance pre- and post-marketing

  • Anticipating drug safety issues in the development of small molecules and biologics

  • What specific and non-specific safety monitoring should be done?

  • Handling safety signals in the development

  • Differences between pre-marketing studies and post-marketing experience

Risk-benefit assessment

  • General principles

  • Quantifying risk

  • Taking action to optimise risk-benefit

  • Monitoring the effectiveness of risk management measures

Clinical trial ADR reporting requirements

  • ICH E2A and general requirements

  • Expedited reports

  • EU Clinical Trials Directive, Clinical Trial Regulation and detailed guidance

  • US IND requirements

  • DSURs

Pharmacoepidemiological studies - basic designs, strengths, weaknesses and examples

  • Real-world data is the king

  • Randomisation in the real world

  • Drugs and devices - it's all 'exposure'

  • Tracking all patients?

Periodic reporting - PSURs and PBRERs

  • Evolution of the PSUR, PBRER and DSUR

  • What do we submit and when to submit it

  • Practical aspects of compiling PSURs and PBRERs

  • Linking DSURs, RMPs, PSURs, PBRERs and core safety information

Drug surveillance in countries outside Europe

  • US culture

  • NDA and IND safety reporting

  • Inspections

  • Japan culture

  • Post-marketing safety surveillance programmes in Japan

  • Pharmacovigilance in other countries

Practicalities of signal detection

  • Definitions of signals

  • Regulatory guidances on signal detection by industry and regulators

  • Resources for signal detection

  • Quantitative vs qualitative signal detection

Examples of pharmacoepidemiological studies used in risk management

  • How we weigh evidence

  • Observational cohort studies

  • Case control studies

  • Drug registries (anti-TNFs)

  • Pregnancy registries

Practicalities of risk management

  • A real-world example of the development of a successful EU RMP

  • Requirements of RMPs from an industry point of view

  • How to write a successful RMP

  • Reporting results of outcomes of activities in the RMP

  • Updating a RMP

Practical pharmacovigilance workshop

  • A practical case study with valuable hands-on experience

  • Handling an important safety alert from regulators

  • Assessment of risk

  • Determining measures to respond to previously unidentified risks

  • Continuing assessment and communication of risk-benefit


  • Glyn Belcher

  • Shelley Gandhi

  • Seema Jaitly

  • John Parkinson

  • Saad Shakir

For more information about this conference visit

View source version on

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting